On February 19, 2009, the US Food and Drug Administration (FDA) approved the licensing of febuxostat for the treatment of hyperuricemia in patients with chronic gout. This is the only approved indication for the drug at this time. Febuxostat will be marketed under the trade name Uloric and is manufactured by Takeda Pharmaceuticals. Links to summaries of clinical trials of febuxostat previously posted on this website are accessed at the following links:
A Small Favor
More than 15 years ago the Arthritis Center launched this website with the mission to bring current and accurate disease education to health care professionals and patients alike. Content on our site is generated directly by our team members. Unlike many health education websites we do not accept advertising, paid guests posts or charge for access to our site.
That’s where you come in. Your support will allow us to continue to deliver this valuable information to over 1 million visitors each year.Contribute TodayMore Ways to Give